So-Young International Inc.
NASDAQ:SYMedical - Healthcare Information Services
-$0.09 today
- Market cap
- $239.36M
- Beta
- 1.98
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.95
Volume 0.46M
Average 0.63M
SY Net Income
Bottom-line profit after all expenses, interest, and taxes.
So-Young International Inc.NASDAQ: SY
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -CN¥48.88M, compared with -CN¥33.14M a year earlier. Trailing-twelve-month net income was -CN¥256.54M.
Context
- Net income amounted to 15.9% of revenue in FY2025, down 24.3 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -CN¥206.31M (+12.5%) for the fiscal year ending Dec 2026, a slowdown from the +60.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -CN¥48.88M+54.5% QoQ
- Last fiscal yearDec 2025
- -CN¥235.7M+60.0% YoY
- LTMMar 2026
- -CN¥256.54M+57.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -47.5% | -117.7% | -70.2 pp |
| 1 year | +60.0% | +12.5% | -47.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
CNY · from the income statement
- Latest · FY2025
- (235.7M) CNY
- Year-over-year change
- +60.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (235.7M) | +60.0% |
| FY2024 | 2024-12-31 | (589.53M) | -2870.3% |
| FY2023 | 2023-12-31 | 21.28M | +132.5% |
| FY2022 | 2022-12-31 | (65.55M) | -683.1% |
| FY2021 | 2021-12-31 | (8.37M) | — |
Net Income vs competitors
How SY compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +57.3% is the 3rd highest of 11, against a peer median of -6.9%.
- Net income amounts to 15.5% of revenue for SY, versus a peer median of 88.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $86.17M USD | +156.3% | — | 871.0% | |
| LTM Mar 2026 | -$26.09M USD | +85.3% | — | 37.5% | |
| LTM Feb 2026 | -$62.79M USD | -964.8% | — | 78.0% | |
| LTM Mar 2026 | -$80.94M USD | -22.3% | — | 99.7% | |
| LTM Apr 2026 | -$82.7M USD | -96.9% | — | 9.6% | |
| LTM Mar 2026 | -$94.08M USD | +29.1% | — | 109.1% | |
| LTM Mar 2026 | -$99.48M USD | -139.1% | — | 24.2% | |
| LTM Mar 2026 | -$136.99M USD | +8.6% | — | 173.0% | |
| LTM Mar 2026 | -$221.04M USD | -23.7% | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$222.39M USD | +13.8% | — | — |
| LTM Mar 2026 | -CN¥256.54M CNY | +57.3% | — | 15.5% | |
| Peer median (excluding SY) | — | -6.9% | — | 88.8% | |
Competitors are the stored peer set for SY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.69B | 1.26B | 1.5B | 1.47B | 1.48B |
| Cost of Revenue | 327.89M | 393.29M | 544.34M | 567.59M | 774.04M |
| Gross Profit | 1.36B | 864.58M | 953.69M | 899.11M | 707.86M |
| Gross Margin | 80.6% | 68.7% | 63.7% | 61.3% | 47.8% |
| Research & Development | 286.57M | 235.09M | 203.52M | 165.03M | 133.31M |
| Selling, General & Admin | 1.04B | 732.3M | 811.22M | 818.57M | 833.76M |
| Operating Expenses | 1.4B | 967.39M | 1.01B | 1.52B | 967.07M |
| Depreciation & Amortization | 30.08M | 47.09M | 46.09M | 46.09M | 57.21M |
| EBITDA | 63.39M | (39.99M) | 53.96M | (38.39M) | (182.19M) |
| EBITDA Margin | 3.7% | -3.2% | 3.6% | -2.6% | -12.3% |
| Operating Income | (32.57M) | (102.81M) | (61.05M) | (624.49M) | (259.21M) |
| Operating Margin | -1.9% | -8.2% | -4.1% | -42.6% | -17.5% |
| Interest Income | 19.33M | 28.88M | 48.84M | 46.51M | 24.6M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 16.17M | 15.73M | 68.92M | 36.41M | 19.8M |
| Income Before Tax | (16.41M) | (87.07M) | 7.87M | (588.09M) | (239.4M) |
| Pre-Tax Margin | -1.0% | -6.9% | 0.5% | -40.1% | -16.2% |
| Income Tax Expense | 21.23M | (20.97M) | (18.08M) | (905K) | (774.31K) |
| Net Income | (8.37M) | (65.55M) | 21.28M | (589.53M) | (235.7M) |
| Net Margin | -0.5% | -5.2% | 1.4% | -40.2% | -15.9% |
| EPS (Basic) | (0.06) | (0.48) | 0.16 | (4.40) | (1.78) |
| EPS (Diluted) | (0.06) | (0.48) | 0.16 | (4.39) | (1.78) |
| Weighted Avg Shares | 138.04M | 138.04M | 133.19M | 134.09M | 131.59M |
| Weighted Avg Shares (Diluted) | 138.04M | 138.04M | 131.91M | 134.16M | 131.59M |
So-Young International Inc.
NASDAQ:SY
Intrinsic Alpha fair value
Locked
Current Price
$1.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.